1 day ago
1
David Petrus Ibars/iStock via Getty Images
- Eli Lilly (NYSE:LLY) has signed a licensing and development agreement with Camurus to develop long-acting incretin products for conditions such as obesity, diabetes, and other metabolic diseases based on the latter's FluidCrystal technology.
- The deal allows Lilly to develop up
English (US) ·